Anti-tuberculosis Therapeutics Market, Global Outlook and Forecast 2022-2028

April 2022 | 68 pages | ID: A5A375B4B95DEN
Market Monitor Global

Abstracts

Tuberculosis (TB) is a disease affecting the population across the world. Although tuberculosis is a curable disease, it still remains one of the most common causes of death among adults, particularly in the emerging economies.

This report contains market size and forecasts of Anti-tuberculosis Therapeutics in Global, including the following market information:

Global Anti-tuberculosis Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Anti-tuberculosis Therapeutics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Isoniazid Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Anti-tuberculosis Therapeutics include Lupin, Macleods Pharmaceuticals, Otsuka Pharmaceutical, Johnson & Johnson, Pfizer, Novartis, Abbott, AstraZeneca and Bayer, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Anti-tuberculosis Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Anti-tuberculosis Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Anti-tuberculosis Therapeutics Market Segment Percentages, by Type, 2021 (%)

• Isoniazid
• Rifampin
• Ethambutol
• Pyrazinamide
• Otherr

Global Anti-tuberculosis Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Anti-tuberculosis Therapeutics Market Segment Percentages, by Application, 2021 (%)

• Hospitals and Clinics
• Government Agencies
• Non-Profit Organizations
• Others

Global Anti-tuberculosis Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Anti-tuberculosis Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Anti-tuberculosis Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Anti-tuberculosis Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Lupin
• Macleods Pharmaceuticals
• Otsuka Pharmaceutical
• Johnson & Johnson
• Pfizer
• Novartis
• Abbott
• AstraZeneca
• Bayer
• Eli Lilly
• GlaxoSmithKline
• Merck
• Sanofi

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Anti-tuberculosis Therapeutics Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Anti-tuberculosis Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL ANTI-TUBERCULOSIS THERAPEUTICS OVERALL MARKET SIZE

2.1 Global Anti-tuberculosis Therapeutics Market Size: 2021 VS 2028
2.2 Global Anti-tuberculosis Therapeutics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Anti-tuberculosis Therapeutics Players in Global Market
3.2 Top Global Anti-tuberculosis Therapeutics Companies Ranked by Revenue
3.3 Global Anti-tuberculosis Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Anti-tuberculosis Therapeutics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Anti-tuberculosis Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Anti-tuberculosis Therapeutics Players in Global Market
  3.6.1 List of Global Tier 1 Anti-tuberculosis Therapeutics Companies
  3.6.2 List of Global Tier 2 and Tier 3 Anti-tuberculosis Therapeutics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Anti-tuberculosis Therapeutics Market Size Markets, 2021 & 2028
  4.1.2 Isoniazid
  4.1.3 Rifampin
  4.1.4 Ethambutol
  4.1.5 Pyrazinamide
  4.1.6 Otherr
4.2 By Type - Global Anti-tuberculosis Therapeutics Revenue & Forecasts
  4.2.1 By Type - Global Anti-tuberculosis Therapeutics Revenue, 2017-2022
  4.2.2 By Type - Global Anti-tuberculosis Therapeutics Revenue, 2023-2028
  4.2.3 By Type - Global Anti-tuberculosis Therapeutics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Anti-tuberculosis Therapeutics Market Size, 2021 & 2028
  5.1.2 Hospitals and Clinics
  5.1.3 Government Agencies
  5.1.4 Non-Profit Organizations
  5.1.5 Others
5.2 By Application - Global Anti-tuberculosis Therapeutics Revenue & Forecasts
  5.2.1 By Application - Global Anti-tuberculosis Therapeutics Revenue, 2017-2022
  5.2.2 By Application - Global Anti-tuberculosis Therapeutics Revenue, 2023-2028
  5.2.3 By Application - Global Anti-tuberculosis Therapeutics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Anti-tuberculosis Therapeutics Market Size, 2021 & 2028
6.2 By Region - Global Anti-tuberculosis Therapeutics Revenue & Forecasts
  6.2.1 By Region - Global Anti-tuberculosis Therapeutics Revenue, 2017-2022
  6.2.2 By Region - Global Anti-tuberculosis Therapeutics Revenue, 2023-2028
  6.2.3 By Region - Global Anti-tuberculosis Therapeutics Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Anti-tuberculosis Therapeutics Revenue, 2017-2028
  6.3.2 US Anti-tuberculosis Therapeutics Market Size, 2017-2028
  6.3.3 Canada Anti-tuberculosis Therapeutics Market Size, 2017-2028
  6.3.4 Mexico Anti-tuberculosis Therapeutics Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Anti-tuberculosis Therapeutics Revenue, 2017-2028
  6.4.2 Germany Anti-tuberculosis Therapeutics Market Size, 2017-2028
  6.4.3 France Anti-tuberculosis Therapeutics Market Size, 2017-2028
  6.4.4 U.K. Anti-tuberculosis Therapeutics Market Size, 2017-2028
  6.4.5 Italy Anti-tuberculosis Therapeutics Market Size, 2017-2028
  6.4.6 Russia Anti-tuberculosis Therapeutics Market Size, 2017-2028
  6.4.7 Nordic Countries Anti-tuberculosis Therapeutics Market Size, 2017-2028
  6.4.8 Benelux Anti-tuberculosis Therapeutics Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Anti-tuberculosis Therapeutics Revenue, 2017-2028
  6.5.2 China Anti-tuberculosis Therapeutics Market Size, 2017-2028
  6.5.3 Japan Anti-tuberculosis Therapeutics Market Size, 2017-2028
  6.5.4 South Korea Anti-tuberculosis Therapeutics Market Size, 2017-2028
  6.5.5 Southeast Asia Anti-tuberculosis Therapeutics Market Size, 2017-2028
  6.5.6 India Anti-tuberculosis Therapeutics Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Anti-tuberculosis Therapeutics Revenue, 2017-2028
  6.6.2 Brazil Anti-tuberculosis Therapeutics Market Size, 2017-2028
  6.6.3 Argentina Anti-tuberculosis Therapeutics Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Anti-tuberculosis Therapeutics Revenue, 2017-2028
  6.7.2 Turkey Anti-tuberculosis Therapeutics Market Size, 2017-2028
  6.7.3 Israel Anti-tuberculosis Therapeutics Market Size, 2017-2028
  6.7.4 Saudi Arabia Anti-tuberculosis Therapeutics Market Size, 2017-2028
  6.7.5 UAE Anti-tuberculosis Therapeutics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Lupin
  7.1.1 Lupin Corporate Summary
  7.1.2 Lupin Business Overview
  7.1.3 Lupin Anti-tuberculosis Therapeutics Major Product Offerings
  7.1.4 Lupin Anti-tuberculosis Therapeutics Revenue in Global Market (2017-2022)
  7.1.5 Lupin Key News
7.2 Macleods Pharmaceuticals
  7.2.1 Macleods Pharmaceuticals Corporate Summary
  7.2.2 Macleods Pharmaceuticals Business Overview
  7.2.3 Macleods Pharmaceuticals Anti-tuberculosis Therapeutics Major Product Offerings
  7.2.4 Macleods Pharmaceuticals Anti-tuberculosis Therapeutics Revenue in Global Market (2017-2022)
  7.2.5 Macleods Pharmaceuticals Key News
7.3 Otsuka Pharmaceutical
  7.3.1 Otsuka Pharmaceutical Corporate Summary
  7.3.2 Otsuka Pharmaceutical Business Overview
  7.3.3 Otsuka Pharmaceutical Anti-tuberculosis Therapeutics Major Product Offerings
  7.3.4 Otsuka Pharmaceutical Anti-tuberculosis Therapeutics Revenue in Global Market (2017-2022)
  7.3.5 Otsuka Pharmaceutical Key News
7.4 Johnson & Johnson
  7.4.1 Johnson & Johnson Corporate Summary
  7.4.2 Johnson & Johnson Business Overview
  7.4.3 Johnson & Johnson Anti-tuberculosis Therapeutics Major Product Offerings
  7.4.4 Johnson & Johnson Anti-tuberculosis Therapeutics Revenue in Global Market (2017-2022)
  7.4.5 Johnson & Johnson Key News
7.5 Pfizer
  7.5.1 Pfizer Corporate Summary
  7.5.2 Pfizer Business Overview
  7.5.3 Pfizer Anti-tuberculosis Therapeutics Major Product Offerings
  7.5.4 Pfizer Anti-tuberculosis Therapeutics Revenue in Global Market (2017-2022)
  7.5.5 Pfizer Key News
7.6 Novartis
  7.6.1 Novartis Corporate Summary
  7.6.2 Novartis Business Overview
  7.6.3 Novartis Anti-tuberculosis Therapeutics Major Product Offerings
  7.6.4 Novartis Anti-tuberculosis Therapeutics Revenue in Global Market (2017-2022)
  7.6.5 Novartis Key News
7.7 Abbott
  7.7.1 Abbott Corporate Summary
  7.7.2 Abbott Business Overview
  7.7.3 Abbott Anti-tuberculosis Therapeutics Major Product Offerings
  7.7.4 Abbott Anti-tuberculosis Therapeutics Revenue in Global Market (2017-2022)
  7.7.5 Abbott Key News
7.8 AstraZeneca
  7.8.1 AstraZeneca Corporate Summary
  7.8.2 AstraZeneca Business Overview
  7.8.3 AstraZeneca Anti-tuberculosis Therapeutics Major Product Offerings
  7.8.4 AstraZeneca Anti-tuberculosis Therapeutics Revenue in Global Market (2017-2022)
  7.8.5 AstraZeneca Key News
7.9 Bayer
  7.9.1 Bayer Corporate Summary
  7.9.2 Bayer Business Overview
  7.9.3 Bayer Anti-tuberculosis Therapeutics Major Product Offerings
  7.9.4 Bayer Anti-tuberculosis Therapeutics Revenue in Global Market (2017-2022)
  7.9.5 Bayer Key News
7.10 Eli Lilly
  7.10.1 Eli Lilly Corporate Summary
  7.10.2 Eli Lilly Business Overview
  7.10.3 Eli Lilly Anti-tuberculosis Therapeutics Major Product Offerings
  7.10.4 Eli Lilly Anti-tuberculosis Therapeutics Revenue in Global Market (2017-2022)
  7.10.5 Eli Lilly Key News
7.11 GlaxoSmithKline
  7.11.1 GlaxoSmithKline Corporate Summary
  7.11.2 GlaxoSmithKline Business Overview
  7.11.3 GlaxoSmithKline Anti-tuberculosis Therapeutics Major Product Offerings
  7.11.4 GlaxoSmithKline Anti-tuberculosis Therapeutics Revenue in Global Market (2017-2022)
  7.11.5 GlaxoSmithKline Key News
7.12 Merck
  7.12.1 Merck Corporate Summary
  7.12.2 Merck Business Overview
  7.12.3 Merck Anti-tuberculosis Therapeutics Major Product Offerings
  7.12.4 Merck Anti-tuberculosis Therapeutics Revenue in Global Market (2017-2022)
  7.12.5 Merck Key News
7.13 Sanofi
  7.13.1 Sanofi Corporate Summary
  7.13.2 Sanofi Business Overview
  7.13.3 Sanofi Anti-tuberculosis Therapeutics Major Product Offerings
  7.13.4 Sanofi Anti-tuberculosis Therapeutics Revenue in Global Market (2017-2022)
  7.13.5 Sanofi Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Anti-tuberculosis Therapeutics Market Opportunities & Trends in Global Market
Table 2. Anti-tuberculosis Therapeutics Market Drivers in Global Market
Table 3. Anti-tuberculosis Therapeutics Market Restraints in Global Market
Table 4. Key Players of Anti-tuberculosis Therapeutics in Global Market
Table 5. Top Anti-tuberculosis Therapeutics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Anti-tuberculosis Therapeutics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Anti-tuberculosis Therapeutics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Anti-tuberculosis Therapeutics Product Type
Table 9. List of Global Tier 1 Anti-tuberculosis Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Anti-tuberculosis Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Anti-tuberculosis Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Anti-tuberculosis Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Anti-tuberculosis Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Anti-tuberculosis Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Anti-tuberculosis Therapeutics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Anti-tuberculosis Therapeutics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2023-2028
Table 30. Lupin Corporate Summary
Table 31. Lupin Anti-tuberculosis Therapeutics Product Offerings
Table 32. Lupin Anti-tuberculosis Therapeutics Revenue (US$, Mn), (2017-2022)
Table 33. Macleods Pharmaceuticals Corporate Summary
Table 34. Macleods Pharmaceuticals Anti-tuberculosis Therapeutics Product Offerings
Table 35. Macleods Pharmaceuticals Anti-tuberculosis Therapeutics Revenue (US$, Mn), (2017-2022)
Table 36. Otsuka Pharmaceutical Corporate Summary
Table 37. Otsuka Pharmaceutical Anti-tuberculosis Therapeutics Product Offerings
Table 38. Otsuka Pharmaceutical Anti-tuberculosis Therapeutics Revenue (US$, Mn), (2017-2022)
Table 39. Johnson & Johnson Corporate Summary
Table 40. Johnson & Johnson Anti-tuberculosis Therapeutics Product Offerings
Table 41. Johnson & Johnson Anti-tuberculosis Therapeutics Revenue (US$, Mn), (2017-2022)
Table 42. Pfizer Corporate Summary
Table 43. Pfizer Anti-tuberculosis Therapeutics Product Offerings
Table 44. Pfizer Anti-tuberculosis Therapeutics Revenue (US$, Mn), (2017-2022)
Table 45. Novartis Corporate Summary
Table 46. Novartis Anti-tuberculosis Therapeutics Product Offerings
Table 47. Novartis Anti-tuberculosis Therapeutics Revenue (US$, Mn), (2017-2022)
Table 48. Abbott Corporate Summary
Table 49. Abbott Anti-tuberculosis Therapeutics Product Offerings
Table 50. Abbott Anti-tuberculosis Therapeutics Revenue (US$, Mn), (2017-2022)
Table 51. AstraZeneca Corporate Summary
Table 52. AstraZeneca Anti-tuberculosis Therapeutics Product Offerings
Table 53. AstraZeneca Anti-tuberculosis Therapeutics Revenue (US$, Mn), (2017-2022)
Table 54. Bayer Corporate Summary
Table 55. Bayer Anti-tuberculosis Therapeutics Product Offerings
Table 56. Bayer Anti-tuberculosis Therapeutics Revenue (US$, Mn), (2017-2022)
Table 57. Eli Lilly Corporate Summary
Table 58. Eli Lilly Anti-tuberculosis Therapeutics Product Offerings
Table 59. Eli Lilly Anti-tuberculosis Therapeutics Revenue (US$, Mn), (2017-2022)
Table 60. GlaxoSmithKline Corporate Summary
Table 61. GlaxoSmithKline Anti-tuberculosis Therapeutics Product Offerings
Table 62. GlaxoSmithKline Anti-tuberculosis Therapeutics Revenue (US$, Mn), (2017-2022)
Table 63. Merck Corporate Summary
Table 64. Merck Anti-tuberculosis Therapeutics Product Offerings
Table 65. Merck Anti-tuberculosis Therapeutics Revenue (US$, Mn), (2017-2022)
Table 66. Sanofi Corporate Summary
Table 67. Sanofi Anti-tuberculosis Therapeutics Product Offerings
Table 68. Sanofi Anti-tuberculosis Therapeutics Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Anti-tuberculosis Therapeutics Segment by Type in 2021
Figure 2. Anti-tuberculosis Therapeutics Segment by Application in 2021
Figure 3. Global Anti-tuberculosis Therapeutics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Anti-tuberculosis Therapeutics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Anti-tuberculosis Therapeutics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Anti-tuberculosis Therapeutics Revenue in 2021
Figure 8. By Type - Global Anti-tuberculosis Therapeutics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Anti-tuberculosis Therapeutics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Anti-tuberculosis Therapeutics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Anti-tuberculosis Therapeutics Revenue Market Share, 2017-2028
Figure 12. US Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Anti-tuberculosis Therapeutics Revenue Market Share, 2017-2028
Figure 16. Germany Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 17. France Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Anti-tuberculosis Therapeutics Revenue Market Share, 2017-2028
Figure 24. China Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 28. India Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Anti-tuberculosis Therapeutics Revenue Market Share, 2017-2028
Figure 30. Brazil Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Anti-tuberculosis Therapeutics Revenue Market Share, 2017-2028
Figure 33. Turkey Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Anti-tuberculosis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 37. Lupin Anti-tuberculosis Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Macleods Pharmaceuticals Anti-tuberculosis Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Otsuka Pharmaceutical Anti-tuberculosis Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Johnson & Johnson Anti-tuberculosis Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Pfizer Anti-tuberculosis Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Novartis Anti-tuberculosis Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Abbott Anti-tuberculosis Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. AstraZeneca Anti-tuberculosis Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Bayer Anti-tuberculosis Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Eli Lilly Anti-tuberculosis Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. GlaxoSmithKline Anti-tuberculosis Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Merck Anti-tuberculosis Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Sanofi Anti-tuberculosis Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)